Chinese drug regulator National Medical Products Administration conveyed the message to executives of state-owned drugmakers earlier this year, said the people, who asked not to be identified as the deliberations are private. The directive was to assess the feasibility of replacing US-made healthcare products.
The goods identified for potential replacement — by either sourcing locally or from other ...
Learn more about Bloomberg Tax or Log In to keep reading:
See Breaking News in Context
From research to software to news, find what you need to stay ahead.
Already a subscriber?
Log in to keep reading or access research tools and resources.